VKTX Greg Zante sells $1.9M worth of shares
Feb 01, 2026, 5:34 AM
0.00%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Greg Zante sold 57,661 shares of VKTX on 5 January at $32.09 per share, worth a total of $1.9M. They now own 215,571 VKTX shares, or a 23% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.